ArticleCancer cell international2026
TGFBI deficiency facilitates tumor associated macrophages M2 polarization and angiogenesis to promote pancreatic neuroendocrine neoplasms progression.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- TGFBI in tumors and the tumor immune microenvironment: functional roles, mechanisms, and therapeutic targeting.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundTumor-associated macrophages (TAMs) are key components of the tumor microenvironment (TME) that influence tumor progression through immunomodulation, angiogenesis, and extracellular matrix remodeling. Transforming growth factor-beta-induced protein (TGFBI) has demonstrated context-dependent roles in cancer; however, its function in pancreatic neuroendocrine neoplasms (pNENs) remains unclear. This study investigates the role of TGFBI in the progression of pNENs and its interaction with TAMs.
methodsWe employed lentiviral-mediated knockdown and overexpression systems to modulate TGFBI levels in pNEN cell lines (QGP-1, BON-1) and macrophage-like THP-1 cells. Functional assays, including CCK-8, EdU, transwell migration, and tube formation assays, were conducted to evaluate tumor proliferation, invasion, and angiogenesis. Tumor xenograft models were established to assess in vivo effects. Transcriptomic analyses, including RNA sequencing, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, were performed to explore the underlying molecular mechanisms.
resultsTGFBI is silenced in pNENs and associated with TAM M2 macrophage. Down-regulation of TGFBI in pNEN cells promoted proliferation, migration, and invasion in vitro, as well as tumor growth in vivo. Silencing TGFBI enhanced M2 macrophage polarization, as evidenced by increased CD206 expression and activation of the JAK2/STAT3 pathway. Additionally, TGFBI deficiency facilitated angiogenesis both in vitro and in vivo, accompanied by elevated VEGFA expression. Over-expression of TGFBI or treatment with recombinant protein reversed these pro-tumorigenic effects.
conclusionsTGFBI functions as a tumor suppressor in pNENs by modulating TAM polarization, angiogenesis, and tumor cell behavior, largely through the JAK2/STAT3 signaling pathway. These findings reveal a novel role for TGFBI in the TME of pNENs and suggest its potential as a biomarker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.